Developing disease-modifying therapies for children with type 1 diabetes may require different clinical trial and approval pathways than currently assumed, agreed researchers, ethicists and regulators attending a consensus conference on the topic.

“The promise of disease modifying therapies — that we could prevent or delay the onset of the clinical disease, or we could improve the clinical experience for people with diabetes — has not yet been achieved, but we all want to get there,” said conference co-chair Carla Greenbaum, MD, director of the diabetes program at Benaroya Research Institute in Seattle, which cosponsored the meeting with the American Diabetes Association, Juvenile Diabetes Research Foundation and Type 1 Diabetes Exchange. Read more.